These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 759605

  • 1. The selection and evaluation of new chelating agents for the treatment of iron overload.
    Pitt CG, Gupta G, Estes WE, Rosenkrantz H, Metterville JJ, Crumbliss AL, Palmer RA, Nordquest KW, Hardy KA, Whitcomb DR, Byers BR, Arceneaux JE, Gaines CG, Sciortino CV.
    J Pharmacol Exp Ther; 1979 Jan; 208(1):12-8. PubMed ID: 759605
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of polymeric hydroxamic acid iron chelators for treatment of iron overload.
    Winston A, Varaprasad DV, Metterville JJ, Rosenkrantz H.
    J Pharmacol Exp Ther; 1985 Mar; 232(3):644-9. PubMed ID: 3973822
    [Abstract] [Full Text] [Related]

  • 3. Mechanism of iron chelation in the hypertransfused rat: definition of two alternative pathways of iron mobilization.
    Hershko C, Grady RW, Cerami A.
    J Lab Clin Med; 1978 Aug; 92(2):144-51. PubMed ID: 681807
    [Abstract] [Full Text] [Related]

  • 4. The development of new iron-chelating drugs. II.
    Grady RW, Graziano JH, White GP, Jacobs A, Cerami A.
    J Pharmacol Exp Ther; 1978 Jun; 205(3):575-65. PubMed ID: 660531
    [Abstract] [Full Text] [Related]

  • 5. Hemosiderosis in rodents and the effect of acetohydroxamic acid on urinary iron excretion.
    Corden BJ.
    Exp Hematol; 1986 Nov; 14(10):971-4. PubMed ID: 3770104
    [Abstract] [Full Text] [Related]

  • 6. Iron metabolism and chelation therapy in hemosiderosis.
    Graziano JH.
    Curr Top Hematol; 1978 Nov; 1():127-50. PubMed ID: 400529
    [No Abstract] [Full Text] [Related]

  • 7. The development of new iron-chelating drugs.
    Grady RW, Graziano JH, Akers HA, Cerami A.
    J Pharmacol Exp Ther; 1976 Feb; 196(2):478-85. PubMed ID: 1255491
    [Abstract] [Full Text] [Related]

  • 8. Chronic iron overload: new chelators and new strategies.
    Fairbanks VF.
    J Lab Clin Med; 1978 Aug; 92(2):141-3. PubMed ID: 681806
    [No Abstract] [Full Text] [Related]

  • 9. [Comparative evaluation of two models of hemosiderosis for analysis of iron chelators].
    Minina LT, Prostakova TM, Meshchano AIu, Kol'tsova GN, Bovenko VN.
    Biull Eksp Biol Med; 1996 Sep; 122(9):359-60. PubMed ID: 8974501
    [No Abstract] [Full Text] [Related]

  • 10. Erythropoietin versus iron chelators in anaemia and iron overload.
    Vreugdenhil G, van Herpen C, Koene RA.
    Neth J Med; 1993 Feb; 42(1-2):45-7. PubMed ID: 8446223
    [No Abstract] [Full Text] [Related]

  • 11. Improvement of iron removal from the reticuloendothelial system by liposome encapsulation of N,N'-bis[2-hydroxybenzyl]-ethylenediamine-N,N'-diacetic acid (HBED). Comparison with desferrioxamine.
    Lau EH, Cerny EA, Wright BJ, Rahman YE.
    J Lab Clin Med; 1983 May; 101(5):806-16. PubMed ID: 6403640
    [Abstract] [Full Text] [Related]

  • 12. [Current possibilities in the therapy of iron overload].
    Cermák J.
    Vnitr Lek; 1994 Sep; 40(9):605-8. PubMed ID: 7975366
    [Abstract] [Full Text] [Related]

  • 13. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship.
    Silliman CC, Peterson VM, Mellman DL, Dixon DJ, Hambidge KM, Lane PA.
    J Lab Clin Med; 1993 Jul; 122(1):48-54. PubMed ID: 8320490
    [Abstract] [Full Text] [Related]

  • 14. Chelating agents related to ethylenediamine bis(2-hydroxyphenyl)acetic acid (EDDHA): synthesis, characterization, and equilibrium studies of the free ligands and their Mg2+, Ca2+, Cu2+, and Fe3+ chelates.
    Yunta F, García-Marco S, Lucena JJ, Gómez-Gallego M, Alcázar R, Sierra MA.
    Inorg Chem; 2003 Aug 25; 42(17):5412-21. PubMed ID: 12924915
    [Abstract] [Full Text] [Related]

  • 15. NTP Toxicology and Carcinogenesis Studies of para-Chloroaniline Hydrochloride (CAS No. 20265-96-7) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1989 Jul 25; 351():1-256. PubMed ID: 12704433
    [Abstract] [Full Text] [Related]

  • 16. Iron retention and excretion in mice transfused with homologous or heterologous blood and treated with chelators.
    Gralla EJ, Burgess DH.
    Methods Find Exp Clin Pharmacol; 1982 Jul 25; 4(3):151-9. PubMed ID: 7121126
    [Abstract] [Full Text] [Related]

  • 17. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload.
    Schafer AI, Rabinowe S, Le Boff MS, Bridges K, Cheron RG, Dluhy R.
    Arch Intern Med; 1985 Jul 25; 145(7):1217-21. PubMed ID: 3925909
    [Abstract] [Full Text] [Related]

  • 18. Rhodotorulic acid--investigation of its potential as an iron-chelating drug.
    Grady RW, Peterson CM, Jones RL, Graziano JH, Bhargava KK, Berdoukas VA, Kokkini G, Loukopoulos D, Cerami A.
    J Pharmacol Exp Ther; 1979 Jun 25; 209(3):342-8. PubMed ID: 108388
    [Abstract] [Full Text] [Related]

  • 19. Alternative treatment paradigm for thalassemia using iron chelators.
    Szuber N, Buss JL, Soe-Lin S, Felfly H, Trudel M, Ponka P.
    Exp Hematol; 2008 Jul 25; 36(7):773-85. PubMed ID: 18456387
    [Abstract] [Full Text] [Related]

  • 20. Multidentate terephthalamidate and hydroxypyridonate ligands: towards new orally active chelators.
    Abergel RJ, Raymond KN.
    Hemoglobin; 2011 Jul 25; 35(3):276-90. PubMed ID: 21599440
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.